Next Article in Journal
Correction: Roberts et al. “Satiating Effect of High Protein Diets on Resistance-Trained Individuals in Energy Deficit” Nutrients 2019, 11(1), 56
Previous Article in Journal
Diversity of Gut Microbiota Affecting Serum Level of Undercarboxylated Osteocalcin in Patients with Crohn’s Disease
Article Menu

Export Article

Open AccessArticle

Low-Dose Curcumin Nanoparticles Normalise Blood Pressure in Male Wistar Rats with Diet-Induced Metabolic Syndrome

1
Functional Foods Research Group, University of Southern Queensland, Toowoomba, QLD 4350, Australia
2
School of Health and Wellbeing, University of Southern Queensland, Toowoomba, QLD 4350, Australia
3
Texas A&M Rangel College of Pharmacy, Texas A&M University–College Station, TX 77843, USA
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(7), 1542; https://doi.org/10.3390/nu11071542
Received: 10 June 2019 / Revised: 27 June 2019 / Accepted: 5 July 2019 / Published: 8 July 2019
  |  
PDF [7903 KB, uploaded 8 July 2019]
  |  

Abstract

Nanoparticle formulations improve bioavailability and so may allow low-dose formulations of food-derived compounds such as curcumin to attenuate chronic systemic disease despite intrinsically low oral bioavailability. The current study induced metabolic syndrome in male Wistar rats aged eight–nine weeks using a high-carbohydrate, high-fat diet (H) with corn starch diet (C) as control. Using a reversal protocol, rats were given curcumin as either nanoparticles encapsulated in poly(lactic–co–glycolic acid) (5 mg/kg/day, HCNP) or as an unformulated low dose or high-dose suspension in water (low-dose, 5 mg/kg/day, HC5; high-dose, 100 mg/kg/day, HC100) or blank nanoparticles (HBNP) for the final eight weeks of the 16 week study. We analysed cardiovascular parameters including systolic blood pressure and left ventricular diastolic stiffness along with histopathology, liver parameters including plasma liver enzymes, histopathology and metabolic parameters, including glucose tolerance, blood lipid profile and body composition, and plasma curcumin concentrations. HC100 and HCNP but not HBNP normalised systolic blood pressure (C = 120 ± 4; H = 143 ± 5; HBNP = 141 ± 3; HC5 = 143 ± 4; HC100 = 126 ± 4; HCNP = 128 ± 4 mmHg), left ventricular diastolic stiffness and liver fat deposition. No other improvements were induced in HC100 or HCNP or other intervention groups (HC5 and HBNP). We conclude that 5 mg/kg/day curcumin nanoparticles in H rats showed similar improvements in cardiovascular function as 100 mg/kg/day unformulated curcumin correlating with similar plasma curcumin concentrations. View Full-Text
Keywords: metabolic syndrome; curcumin; nanoparticles; hypertension; obesity; oral bioavailability metabolic syndrome; curcumin; nanoparticles; hypertension; obesity; oral bioavailability
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

du Preez, R.; Pahl, J.; Arora, M.; Ravi Kumar, M.N.V.; Brown, L.; Panchal, S.K. Low-Dose Curcumin Nanoparticles Normalise Blood Pressure in Male Wistar Rats with Diet-Induced Metabolic Syndrome. Nutrients 2019, 11, 1542.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top